New biosimilar aims to match opdivo in melanoma fight
Disease control
Not yet recruiting
This study tests whether a new drug called Bmab1700 works like the approved drug Opdivo in people with melanoma (a serious skin cancer) after their tumor has been completely removed by surgery. The study will involve 120 adults with stage IIB to IV melanoma. The main goal is to c…
Phase: PHASE1 • Sponsor: Biocon Biologics UK PLC • Aim: Disease control
Last updated May 13, 2026 16:03 UTC